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Background: Epstein Barr virus (EBV) infected B cells are 
transformed into lymphoblastoid cell lines. Some researchers 
suggested some a few similarities between this process and 
carcinogenesis. We observed the expression of CD80 and 
CD86, co-stimulatory molecules on EBV-transformed B cells 
and changes of CD54 expression after stimulation of CD80 
and CD86. Methods: CD80 and CD86 were stimulated using 
anti-CD80 and anti-CD86 monoclonal antibodies. To assess 
apoptosis and surface protein expression, flow cytometric 
analysis was performed. Intracellular signal molecules were 
evaluated by RT-PCR and immunoblot. Morphology and lo-
calization of proteins were examined using inverted or con-
focal microscope. Results: Cross-linking of CD80 and CD86 
induced apoptosis and interfered with proliferation of 
EBV-transformed B cells, and dispersion of clumped cells. 
We also examined that their stimulation induced ROS accu-
mulation and reduced CD54 expression. Interestingly, we ob-
served that CD80 and CD86 diminished the expression of 
CD54 in different methods. Both CD80 and CD86 down-
regulated activation of focal adhesion kinase. CD80 stimulus 
inhibited CD54 expression through mainly RhoA inactivation, 
while CD86 down-regulated Ras and JNK phosphorylation. 
Conclusion: These results suggest that co-stimulatory CD80 
and CD86 molecules, expressed EBV-transformed B cells, 
may play a role in apoptosis and cell adhesion.
[Immune Network 2011;11(6):390-398]
INTRODUCTION
Epstein  Barr  virus  (EBV)  is  herpes  virus  type  4  which  was 
first reported by Epstein and Barr at 1964 and over 95% of 
all adults were infected with EBV. This virus infects not only 
specifically human B cells through surface CD21 or MHC mol-
ecules, but also T cell, follicular dendritic cell and epithelial 
cells in a low probability. When EBV infects young children, 
it causes a minor cold-like illness or asymptomatic responses. 
However,  in  adolescents  and  adults,  EBV  may  cause  in-
fectious mononucleosis (1,2). In addition, EBV is deeply asso-
ciated  with  several  tumors  including  Burkitt’s  lymphoma 
Hodgkin’s  disease,  nasopharyngeal  carcinoma,  and  gastric 
c a r c i n o m a  ( 3 , 4 ) .  B e c a u s e  E B V  i s  s o  c o m m o n  a n d  w i d e -
spread,  preventing  its  infection  is  almost  impossible. 
C u r r e n t l y ,  t h e r e  i s  n o  s p e c i f i c  treatment  to  EBV.  Thus  it  is 
important to regulate or modulate EBV-infected cells in living 
person, many scientists have been studying about that. When 
EBV enters human B cells, it conducts either lytic program 
or latency program. Latency program is established in most 
people having EBV infection. EBV infects human B cells in 
vitro, it can transform B cells into lymphoblastoid cell lines 
which are permanently growing. The transformed B cells are 
good models for B cell activation, differentiation, and B cell 
tumorogenesis (5,6). EBV-transformed B cells express several 
activation  markers  such  as  CD38,  CD77  and  costimulatory CD54 Diminishment after Cross-linking of CD80, CD86
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molecules  such  as  CD80  and  CD86. 
  B 7  f a m i l y  i s  r e p r e s e n t a t i v e  c o s t i m u l a t o r y  m o l e c u l e  f o u n d  
on activated antigen presenting cells. There are seven known 
members of the B7 family, B7.1 (CD80), B7.2 (CD86), pro-
grammed death (PD)-L1, PD-L2, B7-H3, B7-H4, and inducible 
costimulatory ligand (ICOS-L). CD80 and CD86 are the most 
well-known B7 molecules. They have different functions de-
pending on receptors of coupling. When CD80 or CD86 inter-
acts with surface CD28 on T cells together with antigen-TCR 
(T  cell  receptor)  binding,  they  can  activate  resting  T  cell. 
However,  they  also  inhibit  activation  of  T  cell,  interacting 
with CTLA-4 (CD152) on activated T cell (7-10). Thus most 
studies about functions of CD80 and CD86 have focused on 
the  activation  and  regulation  of  T  cells  through  CD28  or 
CTLA-4, but downstream signal of CD80 and CD86 is not fully 
understood. As B cell is actually one of antigen presenting 
cells, resting B cell have weak expression of CD86 and no 
expression of  CD80 (11-14).  B  cell receptor  signal induced 
abundant expression of CD86. Lipopolysaccharide, CD40 li-
gand or some cytokines induced CD80 expression on B cells 
(15-19). Some reports showed that stimulation of CD80 and 
CD86 on B cells using anti-CD80 and 86 antibodies stimulated 
cell proliferation, immunoglobulin class switching and germi-
nal center formation (20-23). It was reported that CD80 in-
creased pro-apoptotic molecules and decreased anti-apoptotic 
molecules,  but  CD86  promoted  activation  of  LPS-stimulated 
B  cell  (24). 
    In this study, we investigated increases of CD80 and CD86 
expression  during  transformation  of  B  cell  after  EBV  in-
fection. We aimed to examine the cell proliferation, the mor-
phological change, the alteration of adhesion molecules and 
its signal pathway on EBV-transformed B cells after stimula-
tion  of  CD80  and  CD86  using  anti-CD80  and  CD86  anti-
bodies.
MATERIALS AND METHODS
Preparation of EBV-infectious culture supernatant
EBV  infection  was  induced  using  the  cell-free  supernatant 
containing virus particles. The supernatant was prepared from 
an  EBV-transformed  B95-8  marmoset  cell  line.  Cells  were 
grown in an RPMI-1640 medium (HyClone, Logan, UT, USA) 
supplemented with penicillin, streptomycin, and 10% fetal bo-
vine serum (HyClone) at 37
oC in 5% CO2. The culture super-
natant was harvested, centrifuged (1,000 rpm for 10 minutes) 
and filtered using a 0.2μm pore-sized filter to remove cell 
debris. 
Generation of EBV-transformed B cells
Peripheral blood mononuclear cells (PBMCs) were obtained 
from the blood of 5 healthy volunteers who gave informed 
consent for this study by Ficoll-Paque (Amersham Bioscience, 
Uppsala, Sweden) gradient centrifugation. B cells were puri-
fied from PBMCs using a MACS B cell-negative depletion kit 
(Miltenyi  Biotec,  Bergisch  Gladbach,  Germany).  Purified  B 
cells (4×10
6/ml) were added to EBV stock supernatant in a 
culture  flask,  and  after  2  hours  of  incubation  at  37
oC,  an 
RPMI-1640 culture medium (Hyclone) and 1μg/ml of cyclo-
sporine  A (Sigma-Aldrich, St. Louis, MO,  USA) were added 
to deplete remaining T cells. The cultures were incubated for 
2-4 weeks and observed every day until clumps of EBV-in-
fected B cells were visible and the medium turned yellow. 
Phenotype of transforming cells was monitored using flowcy-
tometer (FACSCalibur, BD Bioscience, San Diego, CA, USA) 
and  confocal  microscope  (510  META,  Carl  Zeiss,  Jena, 
Germany). 
Cross-linking of CD80 and CD86 on EBV-transformed 
B cells
EBV-transformed  cells  (5×10
5  cells/well,  200  ul)  were  in-
cubated  with  anti-CD80,  anti-CD86  or  isotype  control 
(MOPC21, Sigma-Aldrich) for 24 hour at 37
oC. Cells were har-
vested in a 1.5-ml tube and washed twice in cold PBS. Cells 
were used for following experiments. To determine optimal 
conditions, experiments were performed at variable concen-
trations (0.3124, 0.625, 1.25, 2.5 and 5 ug/ml). To inhibit ac-
cumulation of ROS, cells were pretreated with NAC (10 mM, 
an  antioxidant;  Sigma  Aldrich)  for  1  hour. 
Detection of cell proliferation and apoptosis
To examine cell proliferation, alamar blue (Serotec, Raleigh, 
NC, USA) assay was performed at 72 hours after CD80 and 
CD86 stimulation. Alamar blue dye was added (10% by vol-
ume) to each well, and the relative fluorescence (530 nM ex-
citation, 590 nM, 620 nM emission) was detected 7 hours later 
using  a  EL-800  fluorometer  (Bio - T e k ,  W i n n o s k i ,  V T ,  U S A ) .  
Experiments were performed in triplicate, and the relative flu-
orescence value represented the mean fluorescence value de-
termined for each culture. Reduction ratio was calculated by 
manufacturer’s protocol. To detect apoptosis, Cells were in-
cubated  anti-CD80,  anti-CD86  or  MOPC21,  and  then  har-
vested, washed twice with PBS, and resuspended in 100 ul CD54 Diminishment after Cross-linking of CD80, CD86
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Figure 1. CD86 and CD80 expression during EBV-transformation 
process of B cells. Resting B cells purified from human blood were
immortalized with a medium containing EBV particles. Harvesting 
cells at each indicated period, cells were stained with FITC- 
conjugated mouse anti-human CD80 (first lane) or CD86 (third lane)
and PE-conjugated mouse anti-human CD19 (second and fourth 
lane) and analyzed by confocal microscope (×400 magnification) as
described in Materials and Methods. 
of 1×binding buffer (10 mM HEPES/NaOH, pH 7.4; 140 mM 
NaCl; 2.5 mM CaCl2). 2 ul of FITC-conjugated Annexin V (BD 
Bioscience) was added and cells were incubated at room tem-
perature  for  15  minutes  in  the  dark  with  gentle  vortexing. 
Finally, cells were washed out and 400 ul of 1× binding buf-
fer was added to each  tube and  cells were analyzed using 
FACSCalibur  flow  cytometer  (BD  Bioscience). 
Measurement of ROS levels
The ROS level was detected using 2',7'-dichlorofluorescin di-
acetate  (DCFH-DA),  a  fluorescence  probe,  which  could  be 
converted to highly fluorescent dichlorofluorescein (DCF) in 
the  presence  of  intracellular  ROS.  EBV-transformed  B  cells 
were pretreated with 10μM DCFH-DA (Molecular probes) for 
30 minutes. Cells were then stimulated with anti-CD80, an-
ti-CD86 antibody or MOPC. Cells were harvested, and then 
ROS levels determined as a FITC level using a FACSCalibur 
flow  cytometer  (BD  Bioscience).
Reverse transcription-polymerase chain reaction 
Total RNA was isolated using an RNAeasy mini kit (QIAGEN, 
Hilden, Germany). RNA was transcribed into cDNA using oli-
go  (dT)  primers  (Bioneer,  Daejeon,  Korea)  and  reverse 
transcriptase. PCR amplification was performed using specific 
primer sets (Bioneer) for CD54 (forward, 5'-TGG TAG CAG 
CCG  CAG  TCA  TA;  backward,  5'-CTC  CTT  CCT  CTT  GGC 
TTA GT, 250-bp), RhoA (forward, 5'-CTC ATA GTC TTC AGC 
AAG GAC CAG TT; backward, 5'-ATC ATT CCG AAG ATC 
CTT CTT CTT, 309-bp), and Ras (forward, 5'-GAC GGA ATA 
TAA GCT GGT GG; backward, 5'-TAA CTA CCC CTC TGC 
ACG GA, 151-bp). For the control group, a specific primer 
set for beta-actin (forward, 5'-ATC CAC GAA ACT ACC TTC 
AA; backward, 5'-ATC CAC ACG GAG TAC TTG C, 200-bp) 
was used. PCR was performed using AccuPower PCR premix 
(Bioneer).  PCR  products  were  analyzed  by  1%  agarose  gel 
electrophoresis and visualized with ethidium bromide under 
UV  light  using  the  LAS-3000  (Fujifilm,  Tokyo,  Japan).  Data 
were  analyzed  using  ImagaJ  software  (NIH).
Western blot analysis
After stimulation, EBV-transformed B cells were pelleted and 
lysed in RIPA buffer (Elpis biotech, Daejeon, Korea) with pro-
tease  and  phosphatase  inhibitor  cocktail  (Sigma-aldirch). 
Protein concentrations were determined by BCA protein assay 
kit (Promega, Madison, WI, USA). The proteins (10μg/sam-
ple) were immediately heated with sample buffer for 5 mi-
nutes at 100
oC, were subjected to SDS-PAGE on gel contain-
ing  10%  (wt/vol)  acrylamide  under  reducing  conditions. 
Separated  proteins  were  transferred  to  PVDF  membranes 
(Millipore, Bedford, MA, USA), and then the membranes were 
b l o c k e d  w i t h  5 %  s k i m  m i l k .  P r i m a r y  a n t i b o d i e s  ( 1 ：200∼ 
1：1,000)  were  incubated  at  room  temperature  for  1  hour 
and wash out 3 times with TBS-T buffer (0.05% tween-20). 
HRP-conjugated secondary antibodies were further incubated 
for 1 hour. Chemiluminescence was detected using an ECL-kit 
(Enhanced  ChemiLuminescence;  Amersham)  and  LAS-3,000 
(Fujifilm). The following primary antibodies were used: an-
ti-CD54, FAK, p-FAK, JNK, p-JNK, RhoA, beta-actin from Cell 
signaling  (Beverly,  MA,  USA),  anti-c-jun  and  p-c-jun  from 
Santa  Cruz  Biotechnology. 
RESULTS
Proliferation and apoptosis of EBV-transformed B cells 
after CD80 and CD86 stimulation
Freshly isolated B cells did not express both CD80 and CD86 
on  surface  (Fig.  1),  but  intracellular  staining  revealed  that 
CD86 was abundant in B cell cytosol (data not shown). After 
1 week of EBV infection, intracellular and surface expression CD54 Diminishment after Cross-linking of CD80, CD86
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A
B
Figure 2. Proliferation and apoptosis after CD80 and CD86 stimulation. (A) EBV-transformed B cells (4 weeks, 
1×10
4 cells/well) were incubated with 0.01∼10 ug/ml of anti-CD80, anti-CD80, or isotype control (MOPC)
for 72 hours. AlamarBlue dye was then added (10% by volume) to each well and relative fluorescence was
measured 7 hours later using a fluorometer as described in Materials and Methods. Reduction ratio was 
calculated by manufacturer’s protocol. (B) EBV-transformed B cells were incubated with anti-CD80 and CD86
antibodies (0.312∼5 ug/ml) or isotype control antibody (MOPC, 0.312∼5 ug/ml) for 24 hours. The cells were
harvested (5×10
5 cells/well, 200 ul) and then stained with a FITC-conjugated annexin V. Thin line represents
isotype control and thick line represents CD80 or CD86 stimulation.
of CD80 and surface expression of CD86 were increased. At 
4  w e e k  w h i c h  i s  k n o w n  a s  a  s t a b l e  p e r i o d  o f  E B V - t r a n s -
formation, phenotype of most cells was CD19+CD80+CD86+ 
determining by flow cytometric analysis (data not shown). To 
examine cellular response after CD80 and CD86 stimulation, 
EBV-transformed B cells (4 weeks) were incubated with dif-
ferent concentrations of anti-CD80, anti-CD86, or isotype con-
trol (IgG1, MOPC21). Stimulation of CD80 or CD86 inhibited 
cell  proliferation  after  72  hours  incubation  with  0.1∼10 
ug/ml of antibodies (Fig. 2A). In addition, apoptosis was de-
tected at incubation with 0.3125∼5μg/ml of antibodies for 
24  hours  (Fig.  2B).CD54 Diminishment after Cross-linking of CD80, CD86
Ga Bin Park, et al.
394 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 6 December 2011
Figure 3. Reduced expression of CD54 after CD80 and CD86 stimulation. (A) EBV-transformed B cells were incubated with
anti-CD80, anti-CD86, or isotype control antibodies (MOPC) for 3 hours. The cells were observed and visualized using 
inverted microscope (×100 magnification, Leica 351, Wetzlar, Germany). (B) After 3 hours stimulation of CD80 or CD86
(5 ug/ml), flow cytometric analysis was performed to examine surface CD54 expression. Histogram shows the expression 
levels of CD54 by CD80/86 engagement (bold line), isotype-matched control group (MOPC, spotted line), and negative
control (solid line). (C) EBV-transformed B cells (5×10
5 cells/well, 200 ul) were triggered on anti-CD80/86 antibody (5 ug/ml)
plates for 1 hour. The cells were washed three times with PBS. RNA was extracted and cDNA was produced using RT 
premix as described in Materials and Methods. RT-PCR for CD54 was performed. The PCR products obtained were 
electrophoresed on 1% agarose gel. 
Reduction of CD54 expression after CD80 and CD86 
stimulation
Morphological change of cell growth at early time of CD80 
and CD86 stimulation was investigated using inverted micro-
scope  (Leica  351,  Leica,  Wetzlar,  Germany).  We  examined 
that  EBV-transformed  B  cells  were  forming  several  clumps. 
In contrast with isotype control, cells dispersed after 3 hours 
incubation with anti-CD80 or anti-CD86 antibodies (Fig. 3A). 
Because adhesion molecules might be involved in clump for-
mation, we investigated whether CD54, CD44 and CD22 ex-
pression were changed after CD80 and CD86 stimulation us-
ing flow cytometric analysis. Surface CD54 expression was di-
minished after ligation of CD80 and CD86 (Fig. 3B), but CD44 
and  CD22  were  not  changed  (data  not  shown).  RT-PCR 
showed that mRNA of CD54 remarkably was decreased after 
1  hour  of  CD80  or  CD86  stimulation  (Fig.  3C).
ROS generation after CD80 and CD86 stimulation
ROS  (reactive  oxygen  species)  level  was  investigated  after 
CD80 and CD86 stimulation because ROS generation is asso-
c i a t e d  w i t h  c e l l u l a r  s t r e s s .  D C F H - D A  w a s  p r e t r e a t e d  f o r  3 0  
minutes  before  incubation  with  anti-CD80  and  CD86 
antibodies. After 4 hours stimulation, ROS was detected using 
flow cytometry. Ligation of CD80 or CD86 increased ROS lev-
el  on  EBV-transformed  B  cells  (Fig.  4  upper  panel).  Both 
CD80 and CD86 stimulation did not increase ROS generation 
additively more than single stimulation. Pretreatment of NAC 
as a ROS accumulation inhibitor completely blocked ROS gen-
eration by CD80 and CD86 stimulation (Fig. 4 lower panel).CD54 Diminishment after Cross-linking of CD80, CD86
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Figure 4. ROS generation after CD80 and CD86 stimulation. EBV-transformed B cells were pretreated with 10 uM DCFH-DA
(Molecular probes) for 30 minutes. Cells (5×10
5 cells/well, 200 ul) were triggered on anti-CD80/86 antibody (5 ug/ml) plates
for 4 hour. Cells were harvested, and then ROS levels determined using a flow cytometer. Histogram shows ROS level
generated by CD80/86 stimulation (dot line) and isotype control group (MOPC, solid line). NAC pretreatment (10 mM, 1 
hour) preceded all procedures. 
Ras and RhoA inactivation after CD80 and CD86 
stimulation
We  examined  whether  CD80  and  CD86  stimulation  modu-
lated RhoA and Ras expression because CD54 expression is 
able to be regulated by Rho and Ras (25,26). RT-PCR showed 
that  CD80  stimulation  decreased  transcription  of  RhoA  and 
C D 8 6  s t i m u l a t i o n  d e c r e a s e d  t r a n s c r i p t i o n  o f  R a s  ( F i g .  5 A ) .  
Transcription of Raf-1, downstream molecules following Ras 
activation, was decreased after stimulation of either CD80 or 
CD86  (data  not  shown).  For  further  study  of  regulation  of 
RhoA by CD80 stimulation, phosphorylation of focal adhesion 
kinase (FAK), a positive regulator of RhoA was detected using 
immunoblot. Total RhoA and FAK proteins were not changed 
but phophorylated FAK and activated RhoA were diminished 
after stimulation of CD80 using anti-CD80 antibody (Fig. 5B). 
NAC  pretreatment  effectively  recovered  activation  of  both 
FAK and RhoA. Because CD86 stimulation affected only Ras 
transcription, MAPK (mitogen-activated protein kinase) activa-
tion  following  activation  of  Ras  and  Raf-1  was  measured. 
Immunoblot  showed  that  CD86  stimulation  blocked  phos-
phorylations of FAK, JNK, a member of MAPK family (Fig. 
5C). In addition, phosphorylations of c-jun, a target molecule 
of  JNK  were  decreased  after  CD86  stimulation. 
DISCUSSION
EBV  is  herpes  virus  that  infects  only  human,  is  causative 
agent occurring several tumors such as Burkitt’s lymphoma, 
Hodgikin’s  disease,  nasopharyngeal  carcinoma,  and  gastric 
cancer.  Abundant  studies  about  EBV-associated  tumoro-
genesis have been carried out, EBV-transformed B cell in vi-
tro, lymphoblastoid cell line was usually used as a model of 
EBV  tumorogenesis.  During  EBV-transformation  of  human 
primary B cell, induction of activation molecules (e.g., CD23, 
CD30,  CD39,  CD70)  and  adhesion  molecules  (e.g.,  CD54) 
were  observed  (27,28).  These  induced  molecules  were  in-
volved in various cell responses (e.g., apoptosis, proliferation, 
antibody secretion and cytokine production). We investigated 
EBV-transformed  B  cells  induced  CD80  and  CD86,  well- 
known costimulatory molecules (Fig. 1). Interestingly, we ob-
served CD86 was already expressed in cytosol of resting B 
cells  (data  not  shown),  it  was  unclear  why  cytosolic  CD86 CD54 Diminishment after Cross-linking of CD80, CD86
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Figure 5. Activation of RhoA, Ras, FAK, and JNK after CD80 and CD86 stimulation. (A) EBV-transformed B cells (5×10
5
cells/well, 200 ul) were triggered on anti-CD80/86 antibody (5 ug/ml) plates for 1 hour. RNA was extracted and cDNA 
was synthesized in Materials and Methods. RT-PCR for RhoA, Ras, and beta-actin as an normalization control was performed. 
(B, C) EBV-transformed B cells were incubated anti-CD80 or anti-CD86 antibody (5 ug/ml) for 3 hours. Cells was harvested
and lysed in lysis buffer. Immunoblot for indicated molecules in the whole lysate was performed as decribed in Materials 
and Methods. 
did not express on surface. Instead, we focused cell response 
after stimulation of  CD80 and CD86  on  EBV-transformed B 
cells.
    CD80 and CD86 are costimulatory molecules which interact 
with  CD28  and  CTLA-4  on  T  cells.  They  are  expressed  on 
antigen presenting cells such as dendritic cell, macrophage, 
and even B cell. CD80 and CD86 provided necessary co-acti-
vation  signal  into  T  cell  through  interaction  with  CD28. 
However,  CD80  and  CD86  for  B  cell  activation  were 
u n n e c e s s a r y .  R e s t i n g  B  c e l l s  e x p r e s s e d  l i t t l e  C D 8 0  a n d  d i d  
not  express  CD86.  Activation  via  B  cell  receptor  induced 
CD86 expression, and CD40 ligand or IL-4 stimulated CD80 
expression on B cells (15-17). Thus it was not unusual for 
EBV-transformed  B  cells  to  induce  CD80  and  CD86  ex-
pression  because  EBV  impersonated  normal  activation  and 
differentiation of B cells (3). However it was not clear what 
viral molecules involved in CD80 and CD86 induction during 
EBV-transformation. To solve this, further study was required 
a l t h o u g h  v i r a l  l a t e  m e m b r a n e  p r o t e i n s  ( L M P )  w e r e  s t r o n g  
candidate. 
  When CD80 and CD86 were stimulated by monoclonal anti-
body,  EBV-transformed  B  cells  underwent  apoptosis  and 
growth inhibition (Fig. 2). CD80 or CD86 stimulation showed 
results  similar  to  each  other,  but  stimulation  of  both  CD80 
and CD86 on same time did not show additive or synergic 
effects.  This  supported  that  C D 8 0  a n d  C D 8 6  s h a r e d  a  p a r t  
of downstream signal pathway on triggering. However, an-
other  report  suggested  CD86  on  LPS-stimulated  B  cells  in-
creased B cell activation in contrast with pro-apoptotic effect 
o f  C D 8 0  ( 2 4 ) .  T h i s  d i s c r e p a n c y  m i g h t  r e s u l t  f r o m  d i f f e r e n t  
conditions  of  activation.  Both  EBV-transformed  B  cells  and 
activated  B  cell  by  LPS  stimulation  were  not  physiological, 
several viral proteins on EBV-transformed B cells complicated 
this  issue. 
    As  well  as  apoptosis  and  growth  inhibition,  CD80  and 
CD86  stimulation  dispersed  EBV-transformed  B  cells  (Fig. 
3A). Because EBV-transformed B cell did not have ligands in-
teracting  with  CD80  and  CD86,  we  did  not  think  that  an-
ti-CD80  and  CD86  antibody  might  directly  interfere  with 
cell-to-cell adhesion. Interestingly, CD54 (ICAM-1) was dimin-
ished after CD80 and CD86 stimulation (Fig. 3B and C), but 
CD22 or CD44 did not (data not shown). CD54 is well-known 
adhesion molecule and its expression was increased during 
EBV-transformation. We did not examine whether CD54 in-
creased  during  EBV-transformation  was  involved  in  clump 
formation or cell proliferation. However it was possible that 
diminishment of CD54 might be related to cellular response 
because  reduction  of  CD54,  cell  dispersion,  apoptosis  and CD54 Diminishment after Cross-linking of CD80, CD86
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growth  inhibition  occurred  simultaneously.  Several  studies 
that CD54 rescued germinal center B cells from apoptosis and 
provided proliferation signal to T cell (29-31) could support 
this  possibility.  Further  molecular  studies  should  be  per-
formed to elucidate whether CD54 was directly linked to cel-
lular  fate  of  EBV-transformed  B  cells. 
    Regulation of CD54 expression was much complicated [26]. 
Several transcription factors (e.g., NF-κB and AP-1) were in-
volved  in  transcription  of  CD54  and  many  kinases  (e.g., 
MAPK) participated in regulation of CD54. In addition, cell 
stress, cytokine and growth factor affected CD54 expression. 
In this study,  we  focused focal adhesion kinase  (FAK) and 
MAPK  (mitogen-activated  protein  kinase).  FAK  and  MAPK 
were also associated with both Ras activation and RhoA acti-
vation  (25).  CD80  stimulation  inhibited  phosphorylation  of 
FAK and activation of RhoA (Fig. 5A and B). NAC, ROS accu-
mulation inhibitor, completely recover activation of FAK and 
R h o A  ( F i g .  5 B ) .  T h i s  r e s u l t s  s u g g e s t e d  t h a t  R O S  a s  s e c o n d 
messenger might be involved in regulation of CD54 by CD80 
stimulation. In contrast with CD80, CD86 stimulation blocked 
Ras transcription (Fig. 5A) and phosphorylation of FAK, JNK, 
and c-jun (Fig. 5C), but did not affect RhoA transcription (Fig. 
5A).  Interestingly,  NAC  did  not  influence  inhibition  of  JNK 
activation  by  CD86  stimulation  (data  not  shown)  although 
CD86 stimulation also increased ROS generation (Fig. 4). This 
s u g g e s t e d  R O S  g e n e r a t i o n  m i g h t  b e  r e l a t e d  t o  R h o A  i n -
activation,  but  its  mechanism  remained  unclear.  Although 
both  CD80  and  CD86  stimulation  reduced  transcription  of 
Raf-1 as a downstream molecule of Ras (data not shown), we 
focused  on  MAPK  phosphorylation  following  CD86  stim-
ulation alone because CD80 stimulation was related to rather 
RhoA than Ras. However, it strongly suggested a possibility 
that not only CD86 but also CD80 stimulation reduced CD54 
expression  partially  through  MAPK  pathway.  Further  study 
was  necessary  to  solve  these  problems.
    Taken together, we observed that CD80 and CD86 induced 
during  EBV-transformation  of  B  cell  were  able  to  induce 
apoptosis,  growth  inhibition,  and  reduction  of  CD54 
expression. In addition, we suggested that decrease of CD54 
by CD80 and CD86 regulated through inactivation of RhoA 
and  Ras  respectively.  These  results  contribute  to  under-
standing the function of CD80 and CD86 on activated B cell 
or B lymphoma. Also, it may support fundamental data and 
the possibility of CD80 and CD86 as a target to treat EBV-as-
sociated  diseases.
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